ArticleThe British journal of ophthalmology2005
Interferon as a treatment for uveitis associated with multiple sclerosis.
Article in The British journal of ophthalmology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00344253 (A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis), which is not on this map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM)
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Interferons in vitreoretinal diseases; a review on their clinical application, and mechanism of action.International ophthalmology · 2024Pooled it
- Pooled it
- [DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017Guideline
- Interferon as a novel agent for management of macular edema: Where do we stand?Indian journal of ophthalmology · 2026Review
- Noninfectious uveitis: Management with biologic agents.Indian journal of ophthalmology · 2026Review
- [Uveitis and multiple sclerosis : Clinical aspects, diagnostics, management and treatment].Die Ophthalmologie · 2024Review
- Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.Frontiers in ophthalmology · 2024Review
- Pathogenesis and current therapies for non-infectious uveitis.Clinical and experimental medicine · 2023Review
- [Noninfectious posterior uveitis : Clinical aspects, diagnostics, management and treatment].Die Ophthalmologie · 2023Article
- Topical interferon - A novel treatment for pseudophakic macular edema.Indian journal of ophthalmology · 2021Article
- New pharmacotherapy options for noninfectious posterior uveitis.International ophthalmology · 2021Review
- Bilateral Anterior and Intermediate Uveitis with Occlusive Vasculitis as Sole Manifestation of Relapse in Multiple Sclerosis.Case reports in ophthalmological medicine · 2019Article
- [Intraocular inflammation in multiple sclerosis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2018Article
- Alemtuzumab-induced remission of multiple sclerosis-associated uveitis.International ophthalmology · 2017Article
- A review and update on orphan drugs for the treatment of noninfectious uveitis.Clinical ophthalmology (Auckland, N.Z.) · 2017Review
- Acute onset of fingolimod-associated macular edema.American journal of ophthalmology case reports · 2016Article
- Peripheral Vasculitis, Intermediate Uveitis and Interferon Use in Multiple Sclerosis.Turkish journal of ophthalmology · 2016Article
- Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2015Article
- Pharmacotherapy for uveitis: current management and emerging therapy.Clinical ophthalmology (Auckland, N.Z.) · 2014Review
- Ischemic retinal vasculitis and its management.Journal of ophthalmology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn addition to optic neuritis (ON), multiple sclerosis (MS) may also involve the eye with a typically bilateral intermediate uveitis. The aim of this pilot study was to evaluate the efficacy of type I interferons (IFN) for the treatment of MS associated uveitis.
methodsIn this non-randomised, retrospective observational case series 13 patients (eight female, five male) with proved MS and associated uveitis from five uveitis centres who were treated with interferon beta1a were included. Visual acuity (VA), cell count in the aqueous humour and vitreous, as well as the presence of cystoid macula oedema (CMO) were observed.
resultsAll except one patient had a bilateral form of intermediate uveitis (total of 24 eyes). Seven patients had documented CMO before IFN treatment (n = 13 eyes). Median duration of treatment was 24.6 months (range 7.9-78.7). VA improved in 17 eyes (comparing VA before therapy and at last follow up); while 10 eyes (36%) improved >or=3 Snellen lines. Aqueous cell count improved by 1.2 (SD 1.1) grades in all eyes. Vitreous cell count improved by 1.7 (1.4) in all eyes. Only two patients still had minimal CMO on last follow up angiographically. CMO resolved after or during IFN treatment in nine eyes.
conclusionsIFN has been shown to have beneficial effects in patients with MS and/or ON. As shown in the models of experimental allergic encephalomyelitis (EAE) and uveitis, the neurological and ophthalmological manifestations seem to share similar pathogenic mechanisms. Treatment of MS associated uveitis with IFN appears to have beneficial effects on VA, intraocular inflammation activity, and the presence of CMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.